Looks like you clickedhttps://www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135400-asco-gu-2022-overall-survival-with-darolutamide-versus-placebo-in-combination-with-docetaxel-and-androgen-deprivation-therapy-for-metastatic-hormone-sensitive-prostate-cancer-in-the-phase-3-arasens-trial.html
If you do not want to visit that page, you can close this browser tab.
